FGF23 and hypophosphatemia: As expected, intraperitoneal injection of 10 μg recombinant FGF23 (rFGF23) over 5 days into 3-month-old wild-type mice caused hyperphosphaturia and hypophosphatemia (Supplementary Fig S3).